Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Shingai, Naoki  [Clear All Filters]
Journal Article
Konuma T, Harada K, Shinohara A, Uchida N, Shingai N, Ito A, Ozawa Y, Tanaka M, Sawa M, Onizuka M, et al. Association of individual comorbidities with outcomes in allogeneic hematopoietic cell transplantation from unrelated adult donors versus unrelated cord blood: A study on behalf of the Donor/Source and Transplant Complications Working Groups of the Japane. Am J Hematol. 2024.
Shingai N, Mizumaki H, Najima Y, Yamada Y, Tran DCao, Haraguchi K, Toya T, Okuyama Y, Doki N, Nannya Y, et al. Case report: Immune pressure on hematopoietic stem cells can drastically expand glycosylphosphatidylinositol-deficient clones in paroxysmal nocturnal hemoglobinuria. Front Immunol. 2023;14:1329403.
Ikegawa S, Doki N, Kurosawa S, Yamaguchi T, Sakaguchi M, Harada K, Yamamoto K, Hino Y, Shingai N, Senoo Y, et al. CD25 expression on residual leukemic blasts at the time of allogeneic hematopoietic stem cell transplantation predicts relapse in patients with acute myeloid leukemia without complete remission. Leuk Lymphoma. 2015:1-14.
Shirane S, Najima Y, Fukushima K, Sekiya N, Funata N, Kishida Y, Nagata A, Yamada Y, Konishi T, Kaito S, et al. Central nervous system mucormycosis in a patient with hematological malignancy: A case report and review of the literature. J Infect Chemother. 2022.
Shingai N, Ota A, Kato K, Kondo K, Sadaga Y, Kato C, Sakai S, Kambara Y, Nabe Y, Asano K, et al. Elevation of urinary liver-type fatty acid-binding protein is a harbinger of poor patient prognosis after allogeneic stem cell transplantation. Transplant Cell Ther. 2023.
Kurihara K, Sadato D, Najima Y, Hirama C, Haraguchi K, Kato K, Kondo K, Sadaga Y, Kato C, Sakai S, et al. [FLT3-ITD mutation-positive acute myeloid leukemia undergoing clonal transition with PTPN11 mutation at relapse]. Rinsho Ketsueki. 2024;65(2):63-68.
Harada Y, Shingai N, Ding Y, Sadato D, Hayashi Y, Yamaguchi M, Okuyama Y, Shimoyama T, Ohashi K, Harada H. Gene Rearrangements of MLL and RUNX1 Sporadically Occur in Normal CD34 Cells Under Cytokine Stimulation. Cancer Sci. 2020.
Nishijima A, Shingai N, Ohta A, Suda K, Omoto K, Ishida S, Yoshioka K, Kurosawa S, Hino Y, Senoo Y, et al. [Kidney transplantation for end-stage renal disease after third allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia]. Rinsho Ketsueki. 2024;65(1):7-12.
Yasuda S, Najima Y, Konishi T, Yamada Y, Nagata A, Takezaki T, Kaito S, Kurosawa S, Sakaguchi M, Harada K, et al. Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study. Leuk Res. 2021;108:106627.
Morita Y, Yagi Y, Kanemasa Y, Sasaki Y, Ishimine K, Hayashi Y, Mino M, Ohigashi A, Tamura T, Nakamura S, et al. [Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant]. Rinsho Ketsueki. 2023;64(7):586-595.
Harada K, Onizuka M, Mori T, Shimizu H, Seo S, Aotsuka N, Takeda Y, Sekiya N, Kusuda M, Fujihara S, et al. Prognostic factors for the development of lower respiratory tract infection after influenza virus infection in allogeneic hematopoietic stem cell transplantation recipients: A KSGCT Multicenter Analysis. Int J Infect Dis. 2023.
Koi S, Shimizu H, Sadaga Y, Kondo K, Kato C, Sakai S, Kambara Y, Konuma R, Atsuta Y, Shimabukuro M, et al. [Ruptured mycotic cerebral aneurysm in an adult T-cell leukemia/lymphoma patient undergoing allogeneic stem cell transplantation]. Rinsho Ketsueki. 2024;65(2):84-89.